205 related articles for article (PubMed ID: 35049232)
1. Relapsed/refractory acute promyelocytic leukemia with RARA-LBD region mutation was salvaged by venetoclax: A case report.
Li Y; Yu J; Xu Q; Zhang K
Medicine (Baltimore); 2021 Dec; 100(48):e28076. PubMed ID: 35049232
[TBL] [Abstract][Full Text] [Related]
2. Venetoclax overcomes resistance to all-trans retinoic acid in a variant acute promyelocytic leukemia with TNRC18::RARA fusion.
Xu J; Li H; Wang Z; Wang M; Li Q; Hang X; Xu J; Ji J; Chen C; Liu Y; Niu T
Mol Carcinog; 2024 Apr; 63(4):553-557. PubMed ID: 38131515
[TBL] [Abstract][Full Text] [Related]
3. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
Marasca R; Zucchini P; Galimberti S; Leonardi G; Vaccari P; Donelli A; Luppi M; Petrini M; Torelli G
Haematologica; 1999 Nov; 84(11):963-8. PubMed ID: 10553155
[TBL] [Abstract][Full Text] [Related]
4. A Case of Relapsed/Refractory CD56-Positive Acute Promyelocytic Leukemia, in Which Complete Molecular Remission Was Achieved Following Combination Therapy with Venetoclax and Azacitidine.
Sekiguchi Y; Tsutsumi H; Gomyo A; Kudo M; Maseki N; Iizaki Y; Kawamura M; Kobayashi K; Nitta H; Noguchi M; Wakita S; Yamaguchi H; Kobayashi H
Gan To Kagaku Ryoho; 2024 Mar; 51(3):291-297. PubMed ID: 38494811
[TBL] [Abstract][Full Text] [Related]
5. Does acute promyelocytic leukemia patient with the STAT5B/RARa fusion gene respond well to decitabine?: A case report and literature review.
Wang L; Yan X; He J
Medicine (Baltimore); 2020 Oct; 99(43):e22923. PubMed ID: 33120845
[TBL] [Abstract][Full Text] [Related]
6. A novel HNRNPC-RARA fusion in acute promyelocytic leukaemia lacking PML-RARA rearrangement, sensitive to venetoclax-based therapy.
Liu M; Zhao X; Pan W; Qian Z; Du M; Wang LM; Huang H; Xiao H
Br J Haematol; 2021 Oct; 195(2):e123-e128. PubMed ID: 34254314
[No Abstract] [Full Text] [Related]
7. PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort study.
Tang FF; Lu SY; Zhao XS; Qin YZ; Liu XH; Jia JS; Wang J; Gong LZ; Jiang Q; Zhao T; Shi HX; Chang YJ; Huang XJ; Jiang H
Br J Haematol; 2021 Dec; 195(5):722-730. PubMed ID: 34405393
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia.
Tomita A; Kiyoi H; Naoe T
Int J Hematol; 2013 Jun; 97(6):717-25. PubMed ID: 23670176
[TBL] [Abstract][Full Text] [Related]
9. CNS relapses of acute promyelocytic leukemia after all-trans retinoic acid.
Burry LD; Seki JT
Ann Pharmacother; 2002 Dec; 36(12):1900-6. PubMed ID: 12452754
[TBL] [Abstract][Full Text] [Related]
10. Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide.
Shepshelovich D; Oniashvili N; Parnes D; Klein A; Muchtar E; Yeshaya J; Aviram A; Rabizadeh E; Raanani P
Cancer Genet; 2015 Nov; 208(11):575-9. PubMed ID: 26471811
[TBL] [Abstract][Full Text] [Related]
11. Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia.
Breccia M; Foà R
Expert Rev Hematol; 2019 Feb; 12(2):81-87. PubMed ID: 30572725
[TBL] [Abstract][Full Text] [Related]
12. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
[TBL] [Abstract][Full Text] [Related]
13. PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia.
Ohnishi K
Int J Clin Oncol; 2007 Oct; 12(5):313-7. PubMed ID: 17929112
[TBL] [Abstract][Full Text] [Related]
14. [Therapy-related acute promyelocytic leukemia with complex karyotype accompanied by cryptic PML/RARA on chromosome 15 by metaphase FISH].
Kashima E; Sugimoto Y; Nato Y; Ino K; Tawara I; Masuya M; Katayama N
Rinsho Ketsueki; 2020; 61(11):1577-1583. PubMed ID: 33298649
[TBL] [Abstract][Full Text] [Related]
15. [Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial].
Chen SJ; Chen LJ; Zhou GB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):1-8. PubMed ID: 15748426
[TBL] [Abstract][Full Text] [Related]
16. Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients.
Lou Y; Ma Y; Sun J; Ye X; Pan H; Wang Y; Qian W; Meng H; Mai W; He J; Tong H; Jin J
Ann Hematol; 2015 Nov; 94(11):1829-37. PubMed ID: 26294332
[TBL] [Abstract][Full Text] [Related]
17. Pulsed ATRA as single therapy restores long-term remission in PML-RARalpha-positive acute promyelocytic leukemia patients: real time quantification of minimal residual disease. A pilot study.
Visani G; Buonamici S; Malagola M; Isidori A; Piccaluga PP; Martinelli G; Ottaviani E; Grafone T; Baccarani M; Tura S
Leukemia; 2001 Nov; 15(11):1696-700. PubMed ID: 11681409
[TBL] [Abstract][Full Text] [Related]
18. All-trans Retinoic Acid, Arsenic Trioxide, and Anthracycline-based Chemotherapy Improves Outcome in Newly Diagnosed Acute Promyelocytic Leukemia Regardless of FLT3-ITD Mutation Status.
Xu LW; Su YZ; Tao HF
Curr Med Sci; 2021 Jun; 41(3):491-497. PubMed ID: 34169421
[TBL] [Abstract][Full Text] [Related]
19. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation.
Kitamura K; Kiyoi H; Yoshida H; Tobita T; Takeshita A; Ohno R; Naoe T
Cancer Chemother Pharmacol; 1997; 40 Suppl():S36-41. PubMed ID: 9272132
[TBL] [Abstract][Full Text] [Related]
20. [Acute promyelocytic leukemia: state-of-the-art management].
Asou N
Rinsho Ketsueki; 2018; 59(6):725-734. PubMed ID: 29973452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
